Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Sarcoma 1Gynecologic 1Gastrointestinal 1

Conditions

Gliosarcoma 22Glioblastoma 22Brain Neoplasms 16Glioma 10Astrocytoma 9Oligodendroglioma 8Central Nervous System Neoplasms 7Squamous Cell Carcinoma of Head and Neck 3Carcinoma, Non-Small-Cell Lung 3Sarcoma 2Salivary Gland Neoplasms 2Rectal Neoplasms 2Pancreatic Neoplasms 2Osteosarcoma 2Medulloblastoma 2Gastrointestinal Stromal Tumors 2Esthesioneuroblastoma, Olfactory 2Esophageal Neoplasms 2Ependymoma 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Anus Neoplasms 2Wilms Tumor 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Stomach Neoplasms 1Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1

Interventions

tislelizumab 2tazemetostat 2belinostat 2spartalizumab 1pembrolizumab 1fludarabine phosphate 1fludarabine 1Temozolomide 1Sorafenib 1Rifampin 1Quality of Life 1Plicamycin 1Pemetrexed 1Patient Reported Outcome Measures 1PM 01183 1OSI 930 1Nivolumab 1Molecular Diagnostic Techniques 1LY2940680 1Itraconazole 1Irinotecan 1Immunotherapy, Adoptive 1Immunotherapy 1Imatinib Mesylate 1Fluorouracil 1Fluorodeoxyglucose F18 1Erlotinib Hydrochloride 1Drug Therapy 1Doxepin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × Erlotinib Hydrochloride × Sarcoma × Clear all
NCT00603356 2011-09-27

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Astellas Pharma Inc

Phase 1 Completed
60 enrolled
GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

Mesothelioma, Neoplasms, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡